Skip to main content

Table 2 Longitudinal associations of patient characteristics with serum bicarbonate levels

From: Variability in monthly serum bicarbonate measures in hemodialysis patients: a cohort study

 

Unadjusted

Multivariable-adjusted

 

Coefficient (95 % CI)

p

Coefficient (95 % CI)

p

Age (per 10 years)

0.45 (0.29 to 0.61)

<0.001

0.07 (−0.10 to 0.25)

0.41

Male

−0.54 (−1.12 to 0.05)

0.07

0.09 (−0.45 to 0.63)

0.75

Race/ethnicity

    

 White

−0.18 (−1.12 to 0.75)

0.70

−0.61 (−1.45 to 0.23)

0.16

 Hispanic/Other

−0.44 (−1.06 to 0.17)

0.16

−0.28 (−0.83 to 0.26)

0.31

BMI

    

 Overweight

0.06 (−0.63 to 0.74)

0.87

−0.14 (−0.74 to 0.46)

0.66

 Obese

−0.01 (−0.74 to 0.72)

0.97

0.16 (−0.48 to 0.80)

0.62

Dialysis access

    

 AVG

0.22 (−0.20 to 0.64)

0.31

−0.18 (−0.60 to 0.24)

0.40

 Tunneled catheter

0.33 (0.01 to 0.64)

0.04

0.11 (−0.21 to 0.43)

0.50

Etiology of ESRD

    

 Diabetes

0.50 (−0.20 to 1.21)

0.16

0.38 (−0.26 to 1.02)

0.24

 Other/Unknown

−0.21 (−1.00 to 0.58)

0.60

0.31 (−0.46 to 1.08)

0.43

Cardiovascular Disease

0.90 (0.31 to 1.48)

0.003

0.41 (−0.18 to 1.01)

0.17

Phosphate binder

    

 >6 pills/day acid precursor

−1.00 (−1.45 to−0.55)

<0.001

−0.49 (−0.95 to−0.03)

0.04

 >3−6 pills/day acid precursor

−0.39 (−0.81 to 0.03)

0.07

0.02 (−0.41 to 0.44)

0.9

 ≤3 pills/day acid precursor

0.002 (−0.38 to 0.39)

0.9

0.27 (−0.13 to 0.66)

0.19

 ≤3 pills/day base precursor

0.004 (−0.37 to 0.37)

0.9

0.29 (−0.08 to 0.66)

0.12

 >3–6 pills/day base precursor

0.04 (−0.35 to 0.43)

0.84

0.36 (−0.04 to 0.75)

0.08

 >6 pills/day base precursor

−0.23 (−0.61 to 0.15)

0.24

0.08 (−0.33 to 0.49)

0.70

IDW gain (kg)

    

 >1–3

−0.28 (−0.60 to 0.05)

0.10

0.26 (−0.04 to 0.56)

0.08

 >3–7

−0.65 (−1.01 to−0.30)

<0.001

0.15 (−0.18 to 0.47)

0.38

Epoetin alpha dose (Units)

    

 ≤5000

0.11 (−0.11 to 0.32)

0.33

−0.01 (−0.20 to 0.19)

0.9

 >5000 – ≤10,000

0.16 (−0.09 to 0.40)

0.16

0.05 (−0.18 to 0.28)

0.69

 ≥10,000

0.04 (−0.30 to 0.38)

0.83

−0.11 (−0.43 to 0.20)

0.47

spKt/V

    

 1.52–1.70

0.12 (−0.8 to 0.32)

0.25

0.25 (0.06 to 0.44)

0.009

 ≥1.71

0.31 (0.07 to 0.55)

0.01

0.39 (0.16 to 0.62)

0.001

nPCR (g/kg/day)

−3.14 (−3.54 to−2.75)

<0.001

−1.08 (−1.52 to −0.64)

<0.001

Serum albumin (g/dL)

−1.06 (−1.32 to−0.80)

<0.001

−0.84 (−1.15 to −0.52)

<0.001

Hemoglobin (g/dL)

−0.25 (−0.30 to −0.19)

<0.001

−0.14 (−0.19 to −0.08)

<0.001

K+ (mEq/L)

−1.13 (−1.25 to −1.00)

<0.001

−0.70 (−0.83 to −0.57)

<0.001

Calcium (mg/dL)

0.74 (0.62 to 0.87)

<0.001

0.95 (0.82 to 1.08)

<0.001

Phosphorus (mg/dL)

−0.63 (−0.68 to −0.57)

<0.001

−0.39 (−0.45 to −0.32)

<0.001

WBC (103/mm3)

    

6.26–8.25

−0.14 (−0.36 to 0.09)

0.23

0.26 (−0.04 to 0.56)

0.08

≥8.26

−0.35 (−0.64 to −0.08)

0.01

−0.35 (−0.61 to −0.10)

0.007

Serum creatinine (mg/dL)

−0.33 (−0.37 to −0.29)

<0.001

−0.14 (−0.19 to −0.08)

<0.001

Time (months)

0.003 (−0.004 to 0.01)

0.40

0.02 (0.01 to 0.03)

<0.001

  1. Abbreviations: CI confidence interval; BMI body-mass index; AVG arteriovenous graft; ESRD end-stage renal disease; ACE-I angiotensin-converting enzyme inhibitor; ARB angiotensin receptor blocker; nPCR normalized protein catabolic rate; spKt/V single-pool Kt/V; WBC white blood cells; IDW interdialytic weight gain
  2. Models included all variables listed in the Table. Reference categories are female for sex; Black for race/ethnicity; normal/underweight for BMI; arteriovenous fistula (AVF) for dialysis access; hypertension for etiology of ESRD; no binder use for phosphate binder; no epoetin alpha use for epoetin alpha dose; 0-1 kg for interdialytic weight gain; ≤1.51 for spKt/V; ≤6.25 103/mm3 for WBC. Bold values indicate p<0.05.